The Latin America, Middle East and Africa Attention Deficit Hyperactivity Disorder Market would witness market growth of 7.3% CAGR during the forecast period (2022-2028).
As novel treatments are released, it will be crucial to assess their cost-effectiveness to give clinicians, third-party payers, patients, and families an idea of their potential worth. In the near future, the market expansion is anticipated to be driven by extensive research studies carried out by organizations to assess the safety and efficacy of medications in patients with ADHD. Positive findings from these investigations create new business prospects.
For example, alpha-2-adrenergic agonists like guanfacine & clonidine, according to a Boston Children's Hospital study from 2021, can be helpful in reducing illness symptoms in children. Additionally, it is shown that these drugs have fewer adverse side effects than other stimulants such as amphetamines (Adderall, Vyvanse), methylphenidate (Ritalin, Concerta), and caffeine, which are frequently used as initial treatments for the disorder. Therefore, the expansion of essential players’ efforts to promote their products is creating new economic opportunities.
Several studies have established a high variation in the prevalence of ADHD in Brazil. Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood. This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation. Similarly, in the Middle East region, the prevalence of ADHD was assessed based on the DSM-IV guidelines in Egypt, Palestine, Saudi Arabia, Tunisia, Oman, Qatar, Lebanon, Tunisia, and Iraq.
The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028. The Argentina market is showcasing a CAGR of 7.9% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 7% during (2022 - 2028).
Based on Drug Type, the market is segmented into Stimulants and Non-stimulants. Based on Stimulants Type, the market is segmented into Amphetamine, Methylphenidate, Lisdexamfetamine and Dexmethylphenidate. Based on Non-stimulants Type, the market is segmented into Atomoxetine, Guanfacine, Clonidine and Others. Based on Demographics, the market is segmented into Adults and Children. Based on Distribution Channel, the market is segmented into Retail Pharmacy and Hospital Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Attention Deficit Hyperactivity Disorder Market is Predict to reach $16.9 Billion by 2028, at a CAGR of 4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc.
By Drug Type
By Demographics
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
